A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

Differing formulations and ratios of the subjects’ medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.

Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.

Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.

The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.

The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.

Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.

The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.

Immunotherapy in multiple sclerosis may increase the risk for conversion from latent to active tuberculosis infection.

This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.

Cognitive impairment is common in patients with multiple sclerosis (MS) and considerably impacts quality of life.

Alemtuzumab is associated with reduced magnetic resonance imaging disease activity and the slowing of brain volume loss over 7 years in patients with relapsing-remitting multiple sclerosis.

Brain volume loss was smaller for all groups after treatment with fingolimod.

TG1101-RMS201 was a multicenter, placebo-controlled, phase 2, 52-week study designed to evaluate the optimal infusion and safety of ublituximab for relapsing multiple sclerosis.

This retrospective cohort study sought to assess the outcomes for individuals with multiple sclerosis who transitioned from natalizumab to dimethyl fumarate.

The VELOCE trial (ClinicalTrials.gov Identifier: NCT02545868) was an open-label, randomized, phase 3b study designed to assess whether ocrelizumab could raise the humoral responses to vaccines in individuals with relapsing multiple sclerosis.

Analysis of yearly lymphocyte counts showed a declining occurrence of all grades of lymphopenia over time, and by year 9, subjects exhibited no cases of lymphopenia.

The multiple-logistic regression analyses determined that the most consistent predictors for negative clinical outcomes in months 12 to 48 were relapses during months 0 to 12 and EDSS scores at baseline and months 0 to 12.

Investigators explored the efficacy and safety of alemtuzumab in patients initially assigned to alemtuzumab in a previous trial followed by alemtuzumab treatment over a 2-year period in a core study plus an additional 4-year period in an extension trial.

Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.

A prospective, blinded, randomized trial comparing once-weekly and twice-weekly IM IFNβ-1a may be indicated.

Patients with higher rates of depression and fatigue were significantly more likely to have lower MMAS-8 adherence scores.

The investigators examined the association between obesity and the age of first symptom(s), number of impaired functional domains, and early relapse activity in patients with MS.